Description: "This book is about the history of emerging new therapies and preventions for a host of human diseases via biotechnology; the science that drives it and the people and companies who transformed that science into the biotechnologies we benefit from"--
Brief description: Dr. Tim Harris is a molecular biologist and biochemist. He started work in the biotech industry almost at its inception. He began his career in 1974, working on animal viruses, and was one of the first scientists to join the U.K. biotech company Celltech in 1981. Subsequently he spent nearly five years at Glaxo Group Research (now GSK) in the United Kingdom as Director of Biotechnology. Tim has founded several biotech companies since moving to the United States in 1993 to be head of R&D at Sequana Therapeutics, a genomics company in San Diego. He founded and ran SGX Pharmaceuticals (acquired by Eli Lilly) and served briefly as the Chief Technology Officer (CTO) and Director of the Advanced Technology Program (ATP) at SAIC-Frederick, Inc. in Maryland. Latterly, Tim moved to Biogen as SVP Translational Medicine in 2011, before joining the haematology spinout Bioverativ, as head of R&D in March 2017 before the company was acquired by Sanofi. Tim is presently a venture partner at SV Health Investors and actively works on behalf of several small biotechnology companies, some of which he founded. He has published more than 100 peer-reviewed research papers and reviews and has written many commentaries for BioCentury and other industry magazines.
Review Quotes: "Unicorns is a new bible for the history of the biotechnology industry. In addition to a remarkable survey of the many biotech stories over the years, Harris also provides important perspective on all the needed elements to build great companies and deliver disruptive innovation to patients."--John Maraganore, CEO and Principal, JMM Innovations, LLC; Founding CEO, Alnylam Pharmaceuticals
"Tim Harris was born to write this book--a fascinating one-man oral history of the biotechnology industry told by an industry insider with authority, verve, and wit. Highly recommended!"--Kevin Davies, author, Editing Humanity and Cracking the Genome"For those who have followed from the outside the spectacular growth of the biotech industry, Tim Harris provides a vivid account from the inside--the people, the science, the finance, the patent disputes, and of course the patients are all deftly woven into a compelling narrative of this magnificent episode in medial history."--Nicholas Wade, science journalist for Nature, Science, and The New York Times"Unicorns takes the reader on a fascinating journey from the beginnings of recombinant DNA technology to today's cutting-edge science and novel therapies. Few people have been part of this extraordinary expedition the way the author has and no one has shared his experiences in such a lucid and captivating style."--Stelios Papadopoulos, ex-Chariman of Biogen and a former biotech investment banker with SG Cowen and PaineWebber